Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
439
archived clinical trials in
Eating Disorder

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Radiant Research, Inc.
mi
from
Akron, OH
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Radiant Research, Inc.
mi
from
Akron, OH
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
The Craig and Frances Lindner Center of Hope
mi
from
Mason, OH
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
The Craig and Frances Lindner Center of Hope
mi
from
Mason, OH
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Trials of America
mi
from
Eugene, OR
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Trials of America
mi
from
Eugene, OR
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Sunstone Medical Research, LLC
mi
from
Medford, OR
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Sunstone Medical Research, LLC
mi
from
Medford, OR
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Lehigh Center for Clinical Research
mi
from
Allentown, PA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
CRI Lifetree
mi
from
Philadelphia, PA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
CRI Lifetree
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Omega Medical Reserach
mi
from
Warwick, RI
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Omega Medical Reserach
mi
from
Warwick, RI
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Psychiatric Medical Associates
mi
from
Plano, TX
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Psychiatric Medical Associates
mi
from
Plano, TX
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Advanced Research Institute
mi
from
Ogden, UT
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Advanced Research Institute
mi
from
Ogden, UT
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
NeuroScience, Inc.
mi
from
Herndon, VA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
NeuroScience, Inc.
mi
from
Herndon, VA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Southern California Research
mi
from
Beverly Hills, CA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Southern California Research
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Florida Clinical Research Center LLC
mi
from
Maitland, FL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Adams Clinical Trials LLC
mi
from
Watertown, MA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Adams Clinical Trials LLC
mi
from
Watertown, MA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Bioscience Research LLC
mi
from
Mt. Kisco, NY
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Bioscience Research LLC
mi
from
Mt. Kisco, NY
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Oregon Center for Clinical Investigators, Inc. (OCCI, Inc.)
mi
from
Portland, OR
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Oregon Center for Clinical Investigators, Inc. (OCCI, Inc.)
mi
from
Portland, OR
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Radiant Research
mi
from
Greer, SC
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Research Associates
mi
from
Nashville, TN
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Research Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Radiant Research, Inc
mi
from
San Antonio, TX
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Radiant Research, Inc
mi
from
San Antonio, TX
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Summit Research Network (Seattle), LLC
mi
from
Seatlle, WA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Summit Research Network (Seattle), LLC
mi
from
Seatlle, WA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Klinische Forschung Berlin-Mitte GmbH
mi
from
Berlin,
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Klinische Forschung Berlin-Mitte GmbH
mi
from
Berlin,
Click here to add this to my saved trials
Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents
Early Identification and Treatment of Anorexia Nervosa
Status: Enrolling
Updated:  11/19/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents
Early Identification and Treatment of Anorexia Nervosa
Status: Enrolling
Updated: 11/19/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns
Characterizing Diurnal Glucose Patterns of Individuals With Type 1 Diabetes and Eating Disorders
Status: Enrolling
Updated:  11/25/2015
Melrose Institute
mi
from
Minneapolis, MN
Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns
Characterizing Diurnal Glucose Patterns of Individuals With Type 1 Diabetes and Eating Disorders
Status: Enrolling
Updated: 11/25/2015
Melrose Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
Status: Enrolling
Updated:  11/30/2015
Park Nicollet Eating Disorder Institute
mi
from
Minneapolis, MN
Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder
Status: Enrolling
Updated: 11/30/2015
Park Nicollet Eating Disorder Institute
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Characteristics of Persons With an Eating Disorder and Type 1 Diabetes
Characteristics of Persons With an Eating Disorder and Type 1 Diabetes and Psychological Comparisons to Persons With an Eating Disorder and No Diabetes
Status: Enrolling
Updated:  11/30/2015
International Diabetes Center
mi
from
Minneapolis, MN
Characteristics of Persons With an Eating Disorder and Type 1 Diabetes
Characteristics of Persons With an Eating Disorder and Type 1 Diabetes and Psychological Comparisons to Persons With an Eating Disorder and No Diabetes
Status: Enrolling
Updated: 11/30/2015
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Novel Motivational Ecological Momentary Intervention for Anorexia Nervosa
Status: Enrolling
Updated:  1/14/2016
Eating Disorders Program, Boston University
mi
from
Boston, MA
A Novel Motivational Ecological Momentary Intervention for Anorexia Nervosa
Status: Enrolling
Updated: 1/14/2016
Eating Disorders Program, Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Hormonal Factors in the Treatment of Anorexia Nervosa
Hormonal Factors in the Treatment of Anorexia Nervosa
Status: Enrolling
Updated:  2/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Hormonal Factors in the Treatment of Anorexia Nervosa
Hormonal Factors in the Treatment of Anorexia Nervosa
Status: Enrolling
Updated: 2/9/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes
Status: Enrolling
Updated:  2/17/2016
International Diabetes Center
mi
from
Minneapolis, MN
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes
Status: Enrolling
Updated: 2/17/2016
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes
Status: Enrolling
Updated:  2/17/2016
International Diabetes Center
mi
from
Minneapolis, MN
Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.
Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes
Status: Enrolling
Updated: 2/17/2016
International Diabetes Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Innovative Clinical Research, Inc
mi
from
Lauderhill, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Innovative Clinical Research, Inc
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Compass Research, LLC: North Clinic
mi
from
Leesburg, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Compass Research, LLC: North Clinic
mi
from
Leesburg, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Scientific Clinical Research
mi
from
North Miami, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Scientific Clinical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Miami Research Associates
mi
from
South Miami, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Capstone Clinical Research
mi
from
Libertyville, IL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Clinical Trials Technology, Inc
mi
from
Prairie Village, KA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Clinical Trials Technology, Inc
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Louisiana Research Associates, Inc.
mi
from
New Orleans, LA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Louisiana Research Associates, Inc.
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
McLean Hospital
mi
from
Belmont, MA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Boston Clinical Trials, INC.
mi
from
Boston, MA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Adams Clinical Trials LLC
mi
from
Watertown, MA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Adams Clinical Trials LLC
mi
from
Watertown, MA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
HBSA-Pacific Institute for Research & Evaluation
mi
from
Albuquerque, NM
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
HBSA-Pacific Institute for Research & Evaluation
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Click here to add this to my saved trials